^
    Back
    Association details:
    Biomarker:RET fusion
    Cancer:Pancreatic Adenocarcinoma
    Drug:Gavreto (pralsetinib) (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Excerpt:
    GAVRETO is a kinase inhibitor indicated for treatment of:...Adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC).
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors

    Published date:
    05/13/2020
    Excerpt:
    Activity of pralsetinib in various RET fusion-positive tumors…Responses were observed in all patients with pancreatic adenocarcinoma (3/3) and cholangiocarcinoma (2/2)...